Editorial Open Access
Volume 3 | Issue 3 | DOI: https://doi.org/10.33696/Neurol.3.066
The Jalisco Mutation: Familiar Alzheimer’s Disease in México
Marco Antonio Meraz-Ríos1,*, Erika Alejandra Cabrera-Reyes1, Mayte Lizeth Padilla-Cristerna1
- 1Molecular Biomedicine Department, Cinvestav-IPN, Mexico
Corresponding Author
Marco Antonio Meraz-Ríos, mmeraz@cinvestav.mx
Received Date: December 19, 2022
Accepted Date: December 20, 2022
Meraz-Ríos MA, Cabrera-Reyes EA, Padilla-Cristerna ML. The Jalisco Mutation: Familiar Alzheimer’s Disease in México. J Exp Neurol. 2022;3(3):75-77.
Copyright: © 2022 Meraz-Ríos MA, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Recommended Articles
Exercise Benefits on Alzheimer’s Disease
Alzheimer’s disease (AD) is an age-related neurodegenerative disorder [1] and the most common cause of human dementia, accounting for approximately 60%?80% of cases. It is estimated that more than 30 million AD patients, and the number likely to increase to over 100 million by 2050 because of the increase of the elderly population [2].
Effect of Exosomes on Alzheimer’s Disease
AD is a neurodegenerative disease characterized by progressive cognitive impairment, behavioral changes, memory loss and executive dysfunction, all of which present serious threats to the health of older people.
Virtual Reality Zoo Therapy: An Interactive Relaxing System for Alzheimer’s Disease
The number of people with Alzheimer’s disease (AD) is on the rise, yet there is no effective pharmacological treatment that can slow or reverse the disease’s progress
Glucose Metabolism is a Better Marker for Predicting Clinical Alzheimer’s Disease than Amyloid or Tau
Alzheimer’s disease (AD) research has long been dominated with communications regarding the amyloid hypothesis and targeting amyloid clearance through pharmacological therapies from the brain [1].
Human Gray and White Matter Metabolomics to Differentiate APOE and Stage Dependent Changes in Alzheimer’s Disease
Alzheimer’s disease (AD) is a leading cause of death and morbidity in the United States [1]. The hallmarks of AD are β-amyloid (Aβ) and tau. However, studies have indicated that metabolic dysfunction may play a more pivotal role in the progression of AD [2]. Glucose hypometabolism and mitochondrial dysfunction are well-known features of AD [2].